These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34024842)

  • 1. New IDEAS Amyloid Imaging 2021 Study: Running in Place with Ineffective Anti-Amyloid Treatments for Alzheimer's Disease Patients.
    Barrio JR; Whitehouse P; Alavi A; Høilund-Carlsen PF
    J Alzheimers Dis; 2021; 82(2):461-462. PubMed ID: 34024842
    [No Abstract]   [Full Text] [Related]  

  • 2. Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer's disease in vivo?
    Nordberg A
    Eur J Nucl Med Mol Imaging; 2004 Nov; 31(11):1540-3. PubMed ID: 15372212
    [No Abstract]   [Full Text] [Related]  

  • 3. Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer's disease in vivo?
    Hardy J
    Eur J Nucl Med Mol Imaging; 2004 Nov; 31(11):1539-40. PubMed ID: 15372211
    [No Abstract]   [Full Text] [Related]  

  • 4. Picture imperfect: Going beyond imaging amyloid in Alzheimer's disease.
    Kincaid E
    Nat Med; 2016 Oct; 22(10):1067-1068. PubMed ID: 27711060
    [No Abstract]   [Full Text] [Related]  

  • 5. 18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective.
    Kung HF; Choi SR; Qu W; Zhang W; Skovronsky D
    J Med Chem; 2010 Feb; 53(3):933-41. PubMed ID: 19845387
    [No Abstract]   [Full Text] [Related]  

  • 6. Shedding Light on the Molecular Pathology of Amyloid Plaques in Transgenic Alzheimer's Disease Mice Using Multimodal MALDI Imaging Mass Spectrometry.
    Kaya I; Zetterberg H; Blennow K; Hanrieder J
    ACS Chem Neurosci; 2018 Jul; 9(7):1802-1817. PubMed ID: 29648443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, Placebo Controlled Trial of NPT088, A Phage-Derived, Amyloid-Targeted Treatment for Alzheimer's Disease.
    Michelson D; Grundman M; Magnuson K; Fisher R; Levenson JM; Aisen P; Marek K; Gray M; Hefti F
    J Prev Alzheimers Dis; 2019; 6(4):228-231. PubMed ID: 31686093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.
    Ikonomovic MD; Buckley CJ; Heurling K; Sherwin P; Jones PA; Zanette M; Mathis CA; Klunk WE; Chakrabarty A; Ironside J; Ismail A; Smith C; Thal DR; Beach TG; Farrar G; Smith AP
    Acta Neuropathol Commun; 2016 Dec; 4(1):130. PubMed ID: 27955679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of optogenetic Amyloid-β distinguishes between metabolic and physical damages in neurodegeneration.
    Lim CH; Kaur P; Teo E; Lam VYM; Zhu F; Kibat C; Gruber J; Mathuru AS; Tolwinski NS
    Elife; 2020 Mar; 9():. PubMed ID: 32228858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The incubation period of Alzheimer's disease and the timing of tau versus amyloid misfolding and spreading within the brain.
    Goudsmit J
    Eur J Epidemiol; 2016 Feb; 31(2):99-105. PubMed ID: 27017509
    [No Abstract]   [Full Text] [Related]  

  • 11. Alzheimer's Disease Mechanisms and Emerging Roads to Novel Therapeutics.
    Sala Frigerio C; De Strooper B
    Annu Rev Neurosci; 2016 Jul; 39():57-79. PubMed ID: 27050320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long night's journey into the day: amyloid-β imaging in Alzheimer's disease.
    Villemagne VL; Rowe CC
    J Alzheimers Dis; 2013; 33 Suppl 1():S349-59. PubMed ID: 22710919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of amyloid plaques by radioligands for Abeta40 and Abeta42: potential imaging agents in Alzheimer's patients.
    Kung MP; Skovronsky DM; Hou C; Zhuang ZP; Gur TL; Zhang B; Trojanowski JQ; Lee VM; Kung HF
    J Mol Neurosci; 2003 Feb; 20(1):15-24. PubMed ID: 12663930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The molecular pathology of Alzheimer's disease.
    Harrington CR
    Neuroimaging Clin N Am; 2012 Feb; 22(1):11-22, vii. PubMed ID: 22284730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer's disease is getting easier to spot.
    Dolgin E
    Nature; 2018 Jul; 559(7715):S10-S12. PubMed ID: 30046081
    [No Abstract]   [Full Text] [Related]  

  • 16. Amyloid Hypothesis: The Emperor's New Clothes?
    Høilund-Carlsen PF; Barrio JR; Werner TJ; Newberg A; Alavi A
    J Alzheimers Dis; 2020; 78(4):1363-1366. PubMed ID: 33164938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Amyloid-plaque imaging of the brain using PET].
    Ossenkoppele R; Tolboom N; Pijnenburg YA; Lammertsma AA; Scheltens P; van Berckel BN
    Ned Tijdschr Geneeskd; 2011; 155():A2981. PubMed ID: 21586182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clearing Amyloid-β through PPARγ/ApoE Activation by Genistein is a Treatment of Experimental Alzheimer's Disease.
    Bonet-Costa V; Herranz-Pérez V; Blanco-Gandía M; Mas-Bargues C; Inglés M; Garcia-Tarraga P; Rodriguez-Arias M; Miñarro J; Borras C; Garcia-Verdugo JM; Viña J
    J Alzheimers Dis; 2016; 51(3):701-11. PubMed ID: 26890773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse.
    Alcolea D; Pegueroles J; Muñoz L; Camacho V; López-Mora D; Fernández-León A; Le Bastard N; Huyck E; Nadal A; Olmedo V; Sampedro F; Montal V; Vilaplana E; Clarimón J; Blesa R; Fortea J; Lleó A
    Ann Clin Transl Neurol; 2019 Sep; 6(9):1815-1824. PubMed ID: 31464088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation by Magnetic Resonance Imaging of the Diagnostic Potential of a Heptapeptide-Functionalized Imaging Probe Targeted to Amyloid-β and Able to Cross the Blood-Brain Barrier.
    André S; Ansciaux E; Saidi E; Larbanoix L; Stanicki D; Nonclercq D; Vander Elst L; Laurent S; Muller RN; Burtea C
    J Alzheimers Dis; 2017; 60(4):1547-1565. PubMed ID: 29036827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.